It has been over a month since the new presidential administration took office in Perú; and the response to the COVID pandemic by the government remains strong.
More and more age-groups are eligible for vaccination and larger geographic segments of the population are receiving their first doses. Projections by the Ministry of Health indicate all eligible citizens will receive their first dose by the end of 2021. This is great news. However, a number of questions remain – will the current vaccine formulations confer immune coverage in response to the rapidly changing variants (NB: Perú is predominately administering the Sinopharm BBIBP-CorV vaccine formulation – which study data indicates has a <51% efficacy rate)? Will a booster vaccine be required to match the evolving viral complexity? And if such, how will Perú secure the millions of additional doses needed to “immune boost” thousands of rural and underserved communities?